Dyne Therapeutics Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
It's my pleasure to introduce our next guest from Dyne Therapeutics, Chief Executive Officer, Josh Brom; and Chief Scientific Officer, Dr. Oxana Beskrovnaya. The format for this session is roughly a 25-minute fireside chat. (Conference Instructions). With that, Josh, Oxana, welcome. Thank you for joining us.
Questions & Answers
Josh, to start out, could you provide a couple minutes of introductory comments about Dyne for investors new to the story?
Yes. Thanks, Keay, I'd be happy to do it. Thanks again so much for having us today. We're excited to join you, and just want to remind everyone that during our discussion, as usual, we'll be making forward-looking statements, so please refer to our SEC filings for more information on that account.
Look, at Dyne, it all starts with our mission. Keay, as you know, we are laser-focused on muscle diseases and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |